# Hope Medicine Inc.

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/hope-medicine-inc
Canonical HTML page: https://getyourbrief.com/entity/hope-medicine-inc

## Timeline

- **2026-03-24**: Phase III Initiation — First patient dosed at Peking Union Medical College Hospital in China.
- **2026-03-24**: Phase III Initiation — First patient dosed at Peking Union Medical College Hospital in China.
- **2026-01-15**: Regulatory Designations — FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
- **2026-01**: Regulatory Designations — HMI-115 receives FDA Fast Track and NMPA Breakthrough Therapy designations.
- **2026**: Trial Expansion — Continued enrollment across global multicenter sites for the 24-week study.
- **2025-Q4**: Phase II Data Publication — Results showing efficacy without hormonal side effects published in The Lancet.
- **2025-Q4**: Phase II Completion — Global multicenter Phase II trial results published in The Lancet showing efficacy and safety.

## Recent coverage (2 stories, network-wide)

### Hope Medicine Doses First Patient in Phase III Trial for Endometriosis Therapy
2026-03-25 12:13:15 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 10

Hope Medicine Inc. has initiated dosing in its Phase III clinical trial for HMI-115, a first-in-class non-hormonal monoclonal antibody for endometriosis. This milestone marks the first time a non-hormonal treatment for this condition has reached Phase III development globally, offering a potential alternative to traditional hormonal therapies.
Full story: https://getbiobrief.com/story/hope-medicine-hmi-115-phase-iii-endometriosis

### Hope Medicine Doses First Phase III Patient for Non-Hormonal Endometriosis Drug
2026-03-25 12:12:33 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 10

Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.
Full story: https://gethealthbrief.com/story/hope-medicine-hmi115-phase-3-endometriosis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.